Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

4.8K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.8K
Acid Halides to Alcohols: LiAlH4 Reduction01:19

Acid Halides to Alcohols: LiAlH4 Reduction

3.3K
Acid halides are reduced to alcohols in the presence of a strong reducing agent like lithium aluminum hydride.
The mechanism proceeds in three steps. First, the nucleophilic hydride ion attacks the carbonyl carbon of the acid halide to form a tetrahedral intermediate. Next, the carbonyl group is re-formed, and the halide ion departs as a leaving group, generating an aldehyde. A second nucleophilic attack by the hydride yields an alkoxide ion, which, upon protonation, gives a primary alcohol as...
3.3K
RLC Series Circuit: Problem-Solving01:30

RLC Series Circuit: Problem-Solving

2.8K
Consider an AC generator with a frequency of 50 hertz and a voltage of 120 volts. The AC generator is connected to an RLC series circuit with a 20-ohms resistor, a 0.2-henry inductor, and a 0.05-farad capacitor. Determine the impedance, current amplitude, and phase difference between the generator's current and emf.
To solve the problem, first, determine the known and unknown quantities in the problem. Recalling the reactance equation for the inductor and capacitor and substituting the values,...
2.8K
Kohlraush’s Law and its Applications01:29

Kohlraush’s Law and its Applications

224
 Kohlrausch's law explains that at infinite dilution, where dissociation is complete, each ion's contribution to the conductivity of the electrolyte is independent of the nature of other ions present in the solution. It also implies that when an electrolyte is highly diluted, the conductance of the electrolyte is the sum of the individual conductances of the ions it generates upon dissociation. The quantity of electricity an ion carries is proportional to its molar ionic conductance, which...
224
Radical Equations01:26

Radical Equations

564
Radical equations are mathematical expressions in which the variable is found within a radical, most commonly a square root or cube root. These equations frequently arise in science, engineering, and real-world measurements involving nonlinear relationships. To solve a radical equation, the standard procedure is to isolate the radical expression and then eliminate the radical by raising each side to a power equal to the index of the radical. This process may lead to extraneous...
564
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-flow nasal cannula versus noninvasive ventilation in stabilized hypercapnic exacerbation: a physiological crossover trial.

Annals of intensive care·2026
Same author

Translation of surface electromyography into a clinically applicable objective bulbar assessment tool to improve measurement-based care in amyotrophic laterals sclerosis.

Frontiers in neuroscience·2026
Same author

The effect of nasal patency and anatomy during asymmetrical nasal high flow.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

Are teachers missing the beat on students' motor competence?

PloS one·2026
Same author

"What about me? I'm supposed to be … superhuman?": exploring staff perspectives on how to deliver high quality psychological care for people living with amyotrophic lateral sclerosis.

Neurodegenerative disease management·2026
Same author

ALSUntangled #82: N-acetylcysteine.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Noninvasive assessment of cardiovascular autonomic reflexes in amyotrophic lateral sclerosis: a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

The connection between unproven stem cell-based interventions and complementary and alternative medicine in crowdfunding for Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Thinning of the oral motor cortex is linked to impaired speech in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Brain activity in an end-stage ALS patient suggests the presence of an unresponsive wakefulness syndrome.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Whole-body muscle MRI improves diagnostic certainty in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K

ALS untangled #83: clenbuterol.

Adam Burgess1, Olivia Allen2, Paul Barkhaus3

  • 1Department of Neurology, Brooke Army Medical Center, San Antonio, TX, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|March 8, 2026
PubMed
Summary
This summary is machine-generated.

Clenbuterol, a potential treatment for amyotrophic lateral sclerosis (ALS), shows possible benefits in early studies but has significant side effects. Further research is needed before it can be recommended for ALS patients.

Keywords:
ALSclenbuterolmuscle atrophyneurodegenerationβ-2 adrenergic agonist

More Related Videos

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 22, 2011

37.6K
Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

23.9K

Related Experiment Videos

Last Updated: May 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 22, 2011

37.6K
Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

23.9K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Muscle Physiology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
  • Current treatments for ALS are limited, driving research into alternative therapies.
  • Clenbuterol, a beta-2 adrenergic agonist, is being investigated for potential therapeutic effects in ALS.

Purpose of the Study:

  • To review the potential of clenbuterol as a treatment for amyotrophic lateral sclerosis (ALS).
  • To evaluate the biological effects of clenbuterol relevant to ALS pathophysiology.
  • To assess the existing evidence and limitations of clenbuterol in ALS treatment.

Main Methods:

  • Review of existing literature on clenbuterol's effects.
  • Analysis of two mouse model studies for motor neuron disease.
  • Examination of two open-label trials in people with ALS.

Main Results:

  • Clenbuterol exhibits properties like muscle hypertrophy induction, mitochondrial function improvement, and neuroinflammation reduction, potentially beneficial for ALS.
  • Preliminary studies in mouse models and human trials suggest possible benefits.
  • Methodological flaws in current studies limit definitive conclusions.
  • Significant and severe side effects were reported, leading to high dropout rates in trials and access programs.

Conclusions:

  • Clenbuterol cannot be currently endorsed as an effective treatment for ALS due to insufficient evidence and safety concerns.
  • Further rigorous studies are warranted to explore clenbuterol or similar beta-2 adrenergic agonists in ALS patients.
  • The potential benefits must be weighed against the significant risk of adverse events.